6) Methods. -For the sake of clarity, please specify stage 5 non dialysis or stage 5 dialysis.
-The analysis of the RRT group is confusing. In the RRT, please analyse separately dialysis patients and kidney transplant recipients (different populations, different GFR stages). You should exclude kidney transplant recipients. Specify dialysis modalities. -Supplementary table 1: Separate results of dialysis or transplant recipients patients. You should not report creatininemia and eGFR if dialysis patients. 7) Methods. In the normal GFR group, as proteinuria was not measured in 94% patients, you can't exclude CKD stage 1 and 2 in this group. Please state it in the limitation section. 8) Some risk factors for fractures are missing in the analysis. These factors are important to eliminate some bias and to understand mechanisms leading to an increase fracture risk in CKD patients, as history of fracture, corticosteroids use especially in the context of the treatments of some glomerulonephritis, biochimic factors (parathormone, calcemia, phosphatemia, 25OH vitamin D, EPP) . Diabetes mellitus should be analysed separately from the other factors of the comorbidity score. See: Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Pimentel A, Ureña-Torres P, Zillikens MC, Bover J, Cohen-Solal M. Kidney Int. 2017 9) As Scottish population may have lower vitamin D levels compared with more southern locations, the external validity of the cohort is questionable. In deed, low vitamin D is associated with an increased fracture risk. 9) In the discussion, you mentioned that « fractures are more likely to be recorded during an admission than at death" but you report the opposite result: "15 individuals had no hip fracture admission recorded but had a hip fracture related death". Did the fractures occur after admission? Please reformulate and explain this result. 10) In the discussion section, please try to explain the mechanisms underlying the association between CKD and fractures.
REVIEWER
Julio Pascual Dept of Nephrology, Hpspital del Mar, Barcelona, Spain REVIEW RETURNED 29-Nov-2017
GENERAL COMMENTS
In this study, Robertson et al. described the risk of: a) hip frac ture; and b) mortality related to hip fracture, amongst CKD population in one region in East Scotland. Although the number of patients included in the study is large, and that confers statistical power, there are several points in this study that need to be clarified in order to consider it for publication. In general, authors should focus in the strengths of the study and their novelties (mortality after hip fracture in CKD 3-5, for instance) and simplify the paper, the results, the number of tables, and all the information they have provided. 
Robertson and collaborators aimed to investigate the incidence and mortality of hip fractures in CKD. This is an interesting study as data are available in the population in dialysis therapy, but are still few in earlier stages of CKD. To assess the fracture rate in 3-5 stages and 5D of CKD, the authors have used the large Glomms-II populationbased cohort in which GFR has been measured at least twice and linked these data with the National Database and National Death record to investigate accurately the fracture incidence. This approach is novel and different than the cohort follow-up in which the collection of hip fracture and death might be underestimated. They found an increased risk of hip fracture from stage 3-4 of renal failure and increased death related to hip fracture. This is in agreement with findings of reported cohorts.
The measurement of GFR should be better described. Since the cohort was followed, it is not clear which GFR measurement was taken into account; was this at the entry of the study or during the follow-up. -Analysis included individuals aged above 15 years. As very few occur before the age of 55 and are likely to be traumatic, the relevance of including young patients does not appear clear although incidence is significantly increased in relation with the low number of events. I am wondering how the analysis included the deterioration of CKD during the course of the observation period. For example, the low rate of fracture in patients with stage 5 is likely related to the transition to dialysis or transplant therapy. It is also not clear how the authors handled the progression of CDK with hip fractures. Table 3 ). Given the lack of an effect for Stages 3-5 combined and no evidence of a dose response (i.e. no increasing MRR with stage) it is hard to place much faith in the result.
REVIEWER

VERSION 1 -AUTHOR RESPONSE
Editorial Request:
-Please revise your title so that it includes your study design. This is the preferred format for the journal. Our title is: "Hip fracture incidence and mortality in chronic kidney disease: the GLOMMS -II cohort record linkage study".
We are unsure what you require, but suggest amending to: "Hip fracture incidence and mortality in chronic kidney disease: the GLOMMS-II record linkage cohort study"
In addition, we would request that the corresponding author be changed to Dr Marks, and have amended the manuscript accordingly.
Reviewer: 1 Reviewer Name: Perrin Peggy Institution and Country: Nephrology and Transplantation Department, University Hospital, Strasbourg, France Competing Interests: None declared
Robertson and colleagues report the results of a large European (Scottish) population based cohort to determine hip fracture incidence and mortality after hip fracture and their associations with early stages of CKD. They found that hip fracture incidence was higher in CKD stage 3 and 4 compared to patients with normal eGFR. Moreover, they showed an impact of CKD stage 4 on mortality post-hip fractures.
This study is consistent with several previous North American and European population cohort studies, consolidates the relationship between CKD and fracture which has not been always consistent in the literature and gives informative data about post hip fracture mortality.
Major comments: 1) This study considers only hip fracture location limiting number of fracture events and the analysis We acknowledged this limitation by highlighting this in the Strengths and Limitations section (P3) and in the limitations section of the discussion (P22). As we were using hospital admission data, other fracture sites may not lead to hospital admissions and also, hip fractures are often used as a tracer condition for fragility fractures at other sites.
We have amended the sentence on P22: "We only considered hip fractures, acknowledging that CKD may be associated with other fracture sites, but assuming that hip fractures would have more complete admission data, and have been used as a tracer condition for fragility fractures at other sites (Kassim 2013)."
2) As the authors mentioned in the discussion section, the study failed to analyse CKD stage 5 group due to insufficient statistical power in this group (few numbers of individuals and therefore not enough fracture events). Only stage 3 and 4 could be analysed. a) Please clearly state this limitation in the abstract and in all the manuscript. b) In the abstract: As stage 5 group can't be analysed, you can't conclude « post hip mortality was only increased in stage 4 ». Please reformulate. c) In the same way, in the discussion section, you mentioned "posthip fracture mortality was little affected by CKD stage 5"Please reformulate.
Thank you for highlighting that this limitation requires further clarification. We did analyse CKD stage 5, but did not find an association, possibly due to low numbers thus less statistical power. We have amended sections as follows:
Abstract (P2) sentence added: "There was only a small number of individuals and events for CKD stage 5, resulting in insufficient statistical power."
Results (P15) we have already reported "There were, however, only small numbers of individuals and events for Stage 5 CKD." Discussion (P20) sentence added "There were, however, only small numbers of individuals and events for CKD stage 5.
We have also amended sentence (P21): "We found that post-hip fracture mortality, amongst those who had a hip fracture admission, was little affected by CKD stages 3-5 overall, except stage 4." 5) Page 3, you mentioned "use of hospital data to ascertain hip fractures acknowledging that not everyone who suffers a hip fracture is admitted to hospital". Hospital admission is indicated for all patients with fractures. Please reformulate. Hospital data may have missed hip fractures as some hip fractures can be asymptomatic or misdiagnosed and so do not lead to hospitalization.
Thank you for highlighting this interesting point. Hospital admission is not indicated in all patients with fractures. Some fractures e,g spinal, and many others may be treated with a conservative approach and not admitted at all. Even in hip fractures some patients who are bed bound and receiving palliative care may not be admitted but treated in nursing home or palliative care facilities.
We have amended the bullet point (P3): "Use of hospital episode data to ascertain hip fracture, acknowledging that a small number of hip fractures may not lead to hospital admission."
We have also amended sentence (P22): "We assessed hip fracture from hospital episode data, and whilst most patients with a hip fracture are admitted to hospital, we recognise that a very small number may not be admitted." 6) Methods.
-For the sake of clarity, please specify stage 5 non dialysis or stage 5 dialysis.
-The analysis of the RRT group is confusing. In the RRT, please analyse separately dialysis patients and kidney transplant recipients (different populations, different GFR stages However we hope that we have now made this clearer by amending sentence (P23): "We were unable to adjust for some factors that have been associated with fracture risk, including previous fracture and low bone mineral density (see note under Table 2 ), however, whatever an individual's risk factors are, we have demonstrated the high risk for the population as a whole." 9) As Scottish population may have lower vitamin D levels compared with more southern locations, the external validity of the cohort is questionable. Indeed, low vitamin D is associated with an increased fracture risk.
You rightly point out that there might be differing exposures to vitamin D depending on latitude, and this may contribute to fracture rate. However, as our exposed (CKD) and unexposed (normal eGFR) groups were from the same population, therefore equivalent Vitamin D exposure, the relative risk will likely be relevant internationally.
We have added a sentence (P23): "Vitamin D exposure may be lower at extreme latitudes, and may contribute to fracture rate. However, in our study, the exposed (CKD) and unexposed (normal eGFR) groups were from the same population, and Vitamin D exposure would be equivalent, therefore the relative risk is likely to be relevant internationally." 9) In the discussion, you mentioned that « fractures are more likely to be recorded during an admission than at death" but you report the opposite result: "15 individuals had no hip fracture admission recorded but had a hip fracture related death". Did the fractures occur after admission? Please reformulate and explain this result.
We agree that if you take these two statements together it might be confusing. Our statement "Fractures are more likely to be recorded correctly during an admission that at death…" (P21/22) refers to the fact that in our cohort, 1076 individuals had a hip fracture admission compared to only 228 having a hip fracture-related death (see Table 2 P16). We highlighted that only 15 individuals who had a hip fracture-related death, had not had a previous admission where hip fracture was recorded on the discharge summary, but this may be due to a variety of reasons, such as coding issues or lack of an admission (as you previously commented). To improve clarity, we have amended as follows: P21/22: "Fractures are more likely to be recorded during an admission than at death, since for admission, a fracture is likely to be a major event, whereas for a death, many other factors may have contributed, and time between fracture and death recording may be lengthy. In our cohort, 1,076 individuals had a hip fracture recorded from an admission compared to only 228 having a hip fracture recorded at death."
P22: "However, we postulate this would be low numbers (we noted only 15 individuals who died with hip fracture as cause of death without a prior hip fracture admission)." 10) In the discussion section, please try to explain the mechanisms underlying the association between CKD and fractures.
We agree it is important to highlight the mechanisms, and have added the following sentence (P20):
"The mechanisms underlying the association between CKD and fractures are likely to be at the metabolic level, due to abnormalities in the parathyroid-calcium-phosphate axis as a result of reduced kidney function.
[34] In addition, CKD may be a marker for frailty, leading to falls and an increased risk of fracture."
Reviewer: 2 Reviewer Name: Julio Pascual Institution and Country: Dept of Nephrology, Hpspital del Mar, Barcelona, Spain Competing Interests: None declared In this study, Robertson et al. described the risk of: a) hip fracture; and b) mortality related to hip fracture, amongst CKD population in one region in East Scotland. Although the number of patients included in the study is large, and that confers statistical power, there are several points in this study that need to be clarified in order to consider it for publication. In general, authors should focus in the strengths of the study and their novelties (mortality after hip fracture in CKD 3-5, for instance) and simplify the paper, the results, the number of tables, and all the information they have provided.
Major comments Study population
The study is based on a cohort recruited in 2003 with very specific characteristics. The authors should justify how this sample can be representative of the population (i.e., they have the same number of people with normal kidney function and with CKD).
We apologise that the representativeness of this population sample to the general population was not clear. For the purposes of comparing risk, we used a random sample of individuals with normal eGFR and all individuals with impaired eGFR. To improve clarity, we have amended the manuscript as follows:
Abstract (P2): "Participants All individuals (≥15 years) with sustained CKD stage 3-5 and those on RRT, and a 20% random sample of those with normal renal function, in the resident population in 2003."
Methods (P5): "All with at least one abnormal measure of kidney function (eGFR <60 mL/min/1.73 m2); a 20% random sample with normal kidney function; a 20% random sample with no measurement of kidney function; and all on maintenance RRT (dialysis and transplants) were included, as described previously."
Results (P10): "There were 19 537 individuals with CKD stage 3-5, 345 on RRT, and 19 748 with normal eGFR (20% random sample)."
In addition, it's been almost 10 years since the follow-up finished. It's impossible to know if new treatments for CKD related hyperparathyroidism might have any impact on these data that now look old.
We acknowledge this limitation and have amended the discussion (P22): 
Statistical approach
The authors should addressed why they chose not to adjust their results for a competing risk analysis, as it has been proven that mortality risk between CKD and non-CKD population is not equal.
We have now added sentences to the limitations section of the discussion (P23): "We did not take into account the competing risk of death, which has been reported to result in an overestimation of the excess risk of hip fracture, [16] however we have demonstrated the high fracture burden seen. Therefore hip fracture avoidance is important and specifically measures to address modifiable risk factors in this population."
There are, as the reviewers are no doubt aware, various arguments for and against the use of a competing risk analysis dependent on what analysis and message you wish to analyse for (see Marks et al. 2014) . We felt that for this analysis we were using the most conservative estimates of risk and thus more reassuring to a mixed audience than using a competing risks method with its known problems for use in interpreting relative risk.
Angharad Marks, Nicholas Fluck, Gordon J. Prescott, et al. Definitions of progression in chronic kidney disease-predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up. Nephrol Dial Transplant (2014) 29: 333-341
Results
The description of CKD population (stages 3-5 and RRT) is not clear. Is RRT not included in the analysis of hip fracture risk? Hip fracture is increased overall between CKD patients 3-5, so it is not in RRT patients?
Thank you for pointing out that our CKD stage 5 group was not described clearly. For the purposes of this study, CKD stage 5 does not include dialysis and transplant. We have made the following amendments in order to improve clarity.
We have amended the sentence in the Methods (P5): "For this study, individuals with sustained CKD stage 3-5 (not dialysis or transplant), on maintenance RRT (dialysis and transplants), and those with normal kidney function are reported only."
Individuals on RRT (dialysis and transplants) are only reported in the descriptive statistics. To clarify this, a sentence has been added to P10 Statistical analyses: "As there was a low number of individuals and events in the RRT group, this group was reported in the descriptive statistics only, but not included in the hip fracture or mortality post hip fracture risk analyses."
Notes have been added below CKD4 is the only one related with mortality after hip fracture. Authors should discuss a possible hypothesis why.
We agree it is important to discuss why CKD stage 4 was the only stage associated with mortality after hip fracture. As highlighted by Reviewer 4, this effect only in CKD stage 4 is likely to be an effect of CKD severity on mortality risk generally, but the effect for CKD stage 5 in this study was attenuated by small numbers. Additionally, despite the large number of individuals in the cohort, only 1,076 had fractures (915 with CKD stage 3-5 and 161 with normal eGFR) thus the effect size would have to be very large to show an effect with these numbers in the exposed and unexposed groups.
We have added a sentence to P21: "Our finding of an effect with stage 4 CKD is consistent with the literature generally -that mortality risk increases with renal function decline. However, in our study the lack of effect with stage 5 is likely due to less statistical power."
Minor comments
In general, the length of the article should be optimized and the presentation of the results and discussion should be simplified and rewritten.
We hope that by amending as per all reviewers' comments, we have improved the clarity of the manuscript.
Abstract
Line 12, seems that the phrase is incomplete. P2, Abstract has been amended to: "Design Record linkage cohort study (GLOMMS -II)" CKD5-specific risks for hip fracture and mortality are missing.
As there were few individuals and events for CKD stage 5, we have not reported results in the abstract, but have reported fully in the results section. We have added a sentence to the Abstract P2: "There was only a small number of individuals and events for CKD stage 5, resulting in insufficient statistical power."
Methods Please consider replacing Figure 1 in the Supplementary material. We have considered this request, but feel that this figure is extremely helpful for understanding followup. As such, we feel (as did Reviewer 4), it is more beneficial to leave this figure in the main manuscript. This is an interesting study as data are available in the population in dialysis therapy, but are still few in earlier stages of CKD. To assess the fracture rate in 3-5 stages and 5D of CKD, the authors have used the large Glomms-II population-based cohort in which GFR has been measured at least twice and linked these data with the National Database and National Death record to investigate accurately the fracture incidence. This approach is novel and different than the cohort follow-up in which the collection of hip fracture and death might be underestimated. They found an increased risk of hip fracture from stage 3-4 of renal failure and increased death related to hip fracture. This is in agreement with findings of reported cohorts.
Results
The measurement of GFR should be better described. Since the cohort was followed, it is not clear which GFR measurement was taken into account; was this at the entry of the study or during the follow-up.
We agree that the effect of eGFR would potentially change over follow-up. For this analysis we wished to examine the effect that might be ascertained at baseline. For clarity, we have added the following sentence (P6): "Renal status was assessed at entry to study." -Analysis included individuals aged above 15 years. As very few occur before the age of 55 and are likely to be traumatic, the relevance of including young patients does not appear clear although incidence is significantly increased in relation with the low number of events.
We agree that hip fractures under age 55 are rare, but as you point out, our findings show that having CKD increases the risk of fracture even at a younger age. Identifying whether were was an increased risk at younger ages was one of the evidence gaps identified and reported in the introduction (P5): "Overall however, many previous studies reporting the effect of CKD on the incidence of hip fracture or mortality post-hip fracture are limited by:-older populations; CKD based on only one measurement of renal function; or reliance on administrative coding for identification of CKD." We had already highlighted this result in the discussion (P20): "We demonstrated that this increased risk was present across all ages; few previous studies included all age ranges [16, 35] and many only included the elderly. [15, [36] [37] [38] 
]"
We have amended sentence (P22) "GLOMMS-II, a large, population-based cohort including adults ≥15 years, uses valid methods for assessing comorbidity, [44] identifying individuals with CKD, [22] and has data-linkage to long-term outcome data."
We have also amended sentence (P23/24): "Our finding that individuals with CKD, particularly more advanced, are at higher risk of hip fracture should encourage better assessment and management of risk factors for fracture and falls, including in younger CKD patients."
I am wondering how the analysis included the deterioration of CKD during the course of the observation period. For example, the low rate of fracture in patients with stage 5 is likely related to the transition to dialysis or transplant therapy. It is also not clear how the authors handled the progression of CDK with hip fractures.
Renal status was assessed at baseline only, thus progression of CKD has not been taken into account. The issue with CKD stage 5 was the low number of individuals and events. CKD status at baseline, not CKD progression, was our exposure of interest. However, we agree that it would be interesting to look at the relationship between CKD progression and risk of fracture in future research.
We have added a sentence to the discussion (P23): "Finally, in this analysis, renal status was assessed at baseline, thus progression of CKD has not been taken into account. We would therefore recommend that the relationship between CKD progression and risk of fracture be investigated in future research."
